T1 Shortening in the Globus Pallidus after Multiple Administrations of Gadobutrol: Assessment with a Multidynamic Multiecho Sequence.

Purpose To determine the association between the administration of the macrocyclic contrast medium gadobutrol and T1 relaxation time in the brains of patients with normal renal function by using multidynamic multiecho (MDME) magnetic resonance (MR) imaging sequences. Materials and Methods The institutional review board approved this retrospective study, and the need to obtain written informed consent was waived. This study included 46 patients (revealed by an electronic medical record search) who had received one or more gadobutrol injections and a maximum of one MR imaging contrast medium injection other than gadobutrol before MDME sequence acquisition. One radiologist performed quantitative analyses of regions of interest on quantitative T1 maps twice to cover the normal-appearing globus pallidus (GP), frontal white matter, frontal cortex, and thalamus. The number of administrations and the cumulative dose of gadobutrol, age, intervals between administrations, sex, and treatment were investigated. Univariable and multivariable linear regression analyses of the T1 values in four brain regions and the GP-to-thalamus signal intensity (SI) ratio were performed. P values of less than the Bonferroni-corrected value of .01 were considered to indicate significant differences. Results Intraobserver reproducibility was good to excellent (intraclass correlation coefficients, 0.62-0.81). Because of high multicollinearity between the number of gadobutrol administrations and accumulated dose (r = 0.96, P < .001), the number of gadobutrol administrations was considered in the regression analyses. T1 shortening in the GP was independently associated with the number of gadobutrol administrations (P = .002). T1 in the other brain regions and the GP-to-thalamus SI ratio were not significantly associated with the number of gadobutrol administrations (P > .01). Conclusion Multiple exposures to gadobutrol are associated with T1 shortening in the GP. © RSNA, 2017 Online supplemental material is available for this article.

[1]  M. Prince,et al.  Signal Change in the Dentate Nucleus on T1-Weighted MR Images After Multiple Administrations of Gadopentetate Dimeglumine Versus Gadobutrol. , 2016, AJR. American journal of roentgenology.

[2]  D. Stojanov,et al.  Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol , 2016, European Radiology.

[3]  Pascal J. Kieslich,et al.  Increased Signal Intensity in the Dentate Nucleus on Unenhanced T1-Weighted Images After Gadobenate Dimeglumine Administration , 2015, Investigative radiology.

[4]  Sylvie Grand,et al.  T1-Weighted Hypersignal in the Deep Cerebellar Nuclei After Repeated Administrations of Gadolinium-Based Contrast Agents in Healthy Rats , 2015, Investigative radiology.

[5]  Örjan Smedby,et al.  Normal Appearing and Diffusely Abnormal White Matter in Patients with Multiple Sclerosis Assessed with Quantitative MR , 2014, PloS one.

[6]  Jeffrey H. Miller,et al.  MRI Brain Signal Intensity Changes of a Child During the Course of 35 Gadolinium Contrast Examinations , 2015, Pediatrics.

[7]  Emanuel Kanal,et al.  Residual or retained gadolinium: practical implications for radiologists and our patients. , 2015, Radiology.

[8]  Vincenzo Di Lazzaro,et al.  Progressive Increase of T1 Signal Intensity of the Dentate Nucleus on Unenhanced Magnetic Resonance Images Is Associated With Cumulative Doses of Intravenously Administered Gadodiamide in Patients With Normal Renal Function, Suggesting Dechelation , 2014, Investigative radiology.

[9]  Daisuke Takenaka,et al.  High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. , 2014, Radiology.

[10]  C. Mallio,et al.  Gadodiamide and Dentate Nucleus T1 Hyperintensity in Patients With Meningioma Evaluated by Multiple Follow-Up Contrast-Enhanced Magnetic Resonance Examinations With No Systemic Interval Therapy. , 2015, Investigative radiology.

[11]  M. Port,et al.  Comparative In Vivo Dissociation of Gadolinium Chelates in Renally Impaired Rats: A Relaxometry Study , 2011, Investigative radiology.

[12]  T. Frenzel,et al.  Signal Increase on Unenhanced T1-Weighted Images in the Rat Brain After Repeated, Extended Doses of Gadolinium-Based Contrast Agents , 2016, Investigative radiology.

[13]  Pasquale Borrelli,et al.  In vivo dentate nucleus MRI relaxometry correlates with previous administration of Gadolinium-based contrast agents , 2016, European Radiology.

[14]  V. Runge.  Safety of the Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging, Focusing in Part on Their Accumulation in the Brain and Especially the Dentate Nucleus , 2016, Investigative radiology.

[15]  M. Castillo,et al.  Signal intensity change on unenhanced T1-weighted images in dentate nucleus following gadobenate dimeglumine in patients with and without previous multiple administrations of gadodiamide , 2016, European Radiology.

[16]  P. Lundberg,et al.  Rapid magnetic resonance quantification on the brain: Optimization for clinical usage , 2008, Magnetic resonance in medicine.

[17]  C. Quattrocchi,et al.  Gadolinium Retention in the Body and Brain: Is It Time for an International Joint Research Effort? , 2017, Radiology.

[18]  H. Jara,et al.  Global and Regional Brain Assessment with Quantitative MR Imaging in Patients with Prior Exposure to Linear Gadolinium-based Contrast Agents. , 2017, Radiology.

[19]  T. Frenzel,et al.  Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C , 2008, Investigative radiology.

[20]  Pascal J. Kieslich,et al.  Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. , 2015, Radiology.

[21]  Richard C. Semelka,et al.  High Signal Intensity in Globus Pallidus and Dentate Nucleus on Unenhanced T1-weighted MR Images: Evaluation of Two Linear Gadolinium-based Contrast Agents. , 2015, Radiology.

[22]  R. Steen,et al.  Age‐related changes in proton T1 values of normal human brain , 1995, Journal of magnetic resonance imaging : JMRI.

[23]  Alexander Radbruch,et al.  High-Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-Weighted Images: Evaluation of the Macrocyclic Gadolinium-Based Contrast Agent Gadobutrol , 2015, Investigative radiology.

[24]  D. Zanon,et al.  Hepatic Gadolinium Deposition and Reversibility after Contrast Agent-enhanced MR Imaging of Pediatric Hematopoietic Stem Cell Transplant Recipients. , 2016, Radiology.

[25]  M. Castillo,et al.  Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update , 2016, American Journal of Neuroradiology.

[26]  D. Yousem,et al.  Hyperintense Dentate Nuclei on T1-Weighted MRI: Relation to Repeat Gadolinium Administration , 2015, American Journal of Neuroradiology.

[27]  K. Maravilla,et al.  Gadolinium tissue deposition in brain and bone. , 2016, Magnetic resonance imaging.

[28]  W. Reddick,et al.  Establishing norms for age-related changes in proton T1 of human brain tissue in vivo. , 1997, Magnetic resonance imaging.

[29]  M. Tweedle,et al.  Comparison of Gd(DTPA-BMA) (Omniscan) Versus Gd(HP-DO3A) (ProHance) Relative to Gadolinium Retention in Human Bone Tissue by Inductively Coupled Plasma Mass Spectroscopy , 2006, Investigative radiology.

[30]  V. Runge.  Macrocyclic Versus Linear Gadolinium Chelates. , 2015, Investigative radiology.

[31]  Shigeru Furui,et al.  High Signal Intensity in Dentate Nucleus on Unenhanced T1-weighted MR Images: Association with Linear versus Macrocyclic Gadolinium Chelate Administration. , 2015, Radiology.

[32]  Martin R Prince,et al.  Extent of Signal Hyperintensity on Unenhanced T1-weighted Brain MR Images after More than 35 Administrations of Linear Gadolinium-based Contrast Agents. , 2017, Radiology.

[33]  D. Hippe,et al.  Macrocyclic and Other Non–Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function , 2016, Investigative radiology.

[34]  E. Lancelot.  Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents: Differences in Long-Term Biodistribution and Excretion , 2016, Investigative radiology.

[35]  Shigeru Furui,et al.  Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy. , 2015, Radiology.

[36]  David F Kallmes,et al.  Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. , 2015, Radiology.